Candidate Biomarkers for Response to Treatment in Psoriatic Disease
Treatment with biologics and MTX affect serum CXCL10, MMP3, S100A8, ACP5, and CCL2 levels in patients with PsA. MMP3, S100A8, ACP5, and CXCL10 have potential use as serum biomarkers to predict response to treatment for PsA.
Authors
- Omar Fernando Cruz-Correa (ORCID: https://orcid.org/0000-0003-3364-6353)
- Dafna D. Gladman (ORCID: https://orcid.org/0000-0002-9074-0592)
- Darshini Ganatra (ORCID: https://orcid.org/0000-0002-3676-9124)
- Rachel Offenheim
Institutions
- University Health Network (CA)
- University of Toronto (CA)
- Muscular Dystrophy Canada (CA)
- Research Canada (CA)
- Krembil Research Institute
Publication Details
- Journal
- The Journal of Rheumatology
- Published
- 2024-09-01
- DOI
- https://doi.org/10.3899/jrheum.2024-0396
- Citations
- 6
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 1.44